The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $12.41 down -1.97% from its previous closing price of $12.66. In other words, the price has decreased by -$1.97 from its previous closing price. On the day, 0.59 million shares were traded. KALV stock price reached its highest trading level at $12.81 during the session, while it also had its lowest trading level at $12.19.
Ratios:
For a deeper understanding of KalVista Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 1.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 09 ’25 when Palleiko Benjamin L sold 32,979 shares for $15.69 per share. The transaction valued at 517,523 led to the insider holds 369,595 shares of the business.
Yea Christopher sold 30,250 shares of KALV for $474,698 on Jul 09 ’25. The CHIEF DEVELOPMENT OFFICER now owns 127,939 shares after completing the transaction at $15.69 per share. On Jun 09 ’25, another insider, Palleiko Benjamin L, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 7,169 shares for $14.50 each. As a result, the insider received 103,950 and left with 315,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 619925440 and an Enterprise Value of 511497888.
Stock Price History:
The Beta on a monthly basis for KALV is -0.09, which has changed by -0.04317653 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $16.32, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is -8.42%, while the 200-Day Moving Average is calculated to be 9.42%.
Shares Statistics:
For the past three months, KALV has traded an average of 1.18M shares per day and 899600 over the past ten days. A total of 49.76M shares are outstanding, with a floating share count of 38.59M. Insiders hold about 22.75% of the company’s shares, while institutions hold 89.31% stake in the company. Shares short for KALV as of 1752537600 were 9251558 with a Short Ratio of 7.87, compared to 1749772800 on 6253523. Therefore, it implies a Short% of Shares Outstanding of 9251558 and a Short% of Float of 20.899999.
Earnings Estimates
The stock of KalVista Pharmaceuticals Inc (KALV) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.75 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$2.81 and -$3.71 for the fiscal current year, implying an average EPS of -$3.31. EPS for the following year is -$2.17, with 7.0 analysts recommending between -$1.7 and -$2.78.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $116.93M in the next fiscal year. The high estimate is $150M and the low estimate is $87.27M.
